Search

Your search keyword '"Ángeles Pérez-Aísa"' showing total 17 results
Start Over Author "Ángeles Pérez-Aísa"
17 results on '"Ángeles Pérez-Aísa"'

1. Comparison of the management of Helicobacter pylori infection between the older and younger European populations

Author

Paulius Jonaitis, Olga P. Nyssen, Ilaria Maria Saracino, Giulia Fiorini, Dino Vaira, Ángeles Pérez-Aísa, Bojan Tepes, Manuel Castro-Fernandez, Manuel Pabón-Carrasco, Alma Keco-Huerga, Irina Voynovan, Alfredo J. Lucendo, Ángel Lanas, Samuel J. Martínez-Domínguez, Enrique Alfaro Almajano, Luis Rodrigo, Ludmila Vologzanina, Natasa Brglez Jurecic, Maja Denkovski, Luis Bujanda, Umud Mahmudov, Mārcis Leja, Frode Lerang, Gülüstan Babayeva, Dmitry S. Bordin, Antonio Gasbarrini, Juozas Kupcinskas, Oleksiy Gridnyev, Theodore Rokkas, Ricardo Marcos-Pinto, Perminder S. Phull, Sinead M. Smith, Ante Tonkić, Doron Boltin, György Miklós Buzás, Štěpán Šembera, Halis Şimşek, Tamara Matysiak-Budnik, Vladimir Milivojevic, Wojciech Marlicz, Marino Venerito, Lyudmila Boyanova, Michael Doulberis, Lisette G. Capelle, Anna Cano-Català, Leticia Moreira, Francis Mégraud, Colm O’Morain, Javier P. Gisbert, Laimas Jonaitis, and Hp-EuReg investigators

Subjects
Medicine, Science
Abstract

Abstract The prevalence of Helicobacter pylori remains high in the older population. Specific age-related peculiarities may impact the outcomes of H. pylori treatment. The aim of the study was to evaluate the diagnostics and effectiveness of H. pylori eradication between the younger and older European populations. “European Registry on H. pylori Management (Hp-EuReg)” data from 2013 to 2022 were analyzed. Patients were divided into older (≥ 60 years) and younger (18–59 years) groups. Modified intention-to-treat (mITT) and per-protocol (PP) analysis was performed. 49,461 patients included of which 14,467 (29%) were older-aged. Concomitant medications and penicillin allergy were more frequent among the older patients. Differences between younger and older populations were observed in treatment duration in first-line treatment and in proton pump inhibitors (PPIs) doses in second-line treatment. The overall incidence of adverse events was lower in the older adults group. The overall first-line treatment mITT effectiveness was 88% in younger and 90% in the older patients (p

Published
2023
Full Text
View/download PDF

2. Corrigendum to 'Dissecting the genetic heterogeneity of gastric cancer'

Author

Timo Hess, Carlo Maj, Jan Gehlen, Oleg Borisov, Stephan L. Haas, Ines Gockel, Michael Vieth, Guillaume Piessen, Hakan Alakus, Yogesh Vashist, Carina Pereira, Michael Knapp, Vitalia Schüller, Alexander Quaas, Heike I. Grabsch, Jessica Trautmann, Ewa Malecka-Wojciesko, Anna Mokrowiecka, Jan Speller, Andreas Mayr, Julia Schröder, Axel M. Hillmer, Dominik Heider, Florian Lordick, Ángeles Pérez-Aísa, Rafael Campo, Jesús Espinel, Fernando Geijo, Concha Thomson, Luis Bujanda, Federico Sopeña, Ángel Lanas, María Pellisé, Claudia Pauligk, Thorsten Oliver Goetze, Carolin Zelck, Julian Reingruber, Emadeldin Hassanin, Peter Elbe, Sandra Alsabeah, Mats Lindblad, Magnus Nilsson, Nicole Kreuser, René Thieme, Francesca Tavano, Roberta Pastorino, Dario Arzani, Roberto Persiani, Jin-On Jung, Henrik Nienhüser, Katja Ott, Ralf R. Schumann, Oliver Kumpf, Susen Burock, Volker Arndt, Anna Jakubowska, Małgorzta Ławniczak, Victor Moreno, Vicente Martín, Manolis Kogevinas, Marina Pollán, Justyna Dąbrowska, Antonio Salas, Olivier Cussenot, Anne Boland-Auge, Delphine Daian, Jean-Francois Deleuze, Erika Salvi, Maris Teder-Laving, Gianluca Tomasello, Margherita Ratti, Chiara Senti, Valli De Re, Agostino Steffan, Arnulf H. Hölscher, Katharina Messerle, Christiane Josephine Bruns, Armands Sīviņš, Inga Bogdanova, Jurgita Skieceviciene, Justina Arstikyte, Markus Moehler, Hauke Lang, Peter P. Grimminger, Martin Kruschewski, Nikolaos Vassos, Claus Schildberg, Philipp Lingohr, Karsten Ridwelski, Hans Lippert, Nadine Fricker, Peter Krawitz, Per Hoffmann, Markus M. Nöthen, Lothar Veits, Jakob R. Izbicki, Adrianna Mostowska, Federico Martinón-Torres, Daniele Cusi, Rolf Adolfsson, Geraldine Cancel-Tassin, Aksana Höblinger, Ernst Rodermann, Monika Ludwig, Gisela Keller, Andres Metspalu, Hermann Brenner, Joerg Heller, Markus Neef, Michael Schepke, Franz Ludwig Dumoulin, Lutz Hamann, Renato Cannizzaro, Michele Ghidini, Dominik Plaßmann, Michael Geppert, Peter Malfertheiner, Olivier Glehen, Tomasz Skoczylas, Marek Majewski, Jan Lubiński, Orazio Palmieri, Stefania Boccia, Anna Latiano, Nuria Aragones, Thomas Schmidt, Mário Dinis-Ribeiro, Rui Medeiros, Salah-Eddin Al-Batran, Mārcis Leja, Juozas Kupcinskas, María A. García-González, Marino Venerito, and Johannes Schumacher

Subjects
Medicine, Medicine (General), R5-920
Published
2023
Full Text
View/download PDF

3. Dissecting the genetic heterogeneity of gastric cancerResearch in context

Author

Timo Hess, Carlo Maj, Jan Gehlen, Oleg Borisov, Stephan L. Haas, Ines Gockel, Michael Vieth, Guillaume Piessen, Hakan Alakus, Yogesh Vashist, Carina Pereira, Michael Knapp, Vitalia Schüller, Alexander Quaas, Heike I. Grabsch, Jessica Trautmann, Ewa Malecka-Wojciesko, Anna Mokrowiecka, Jan Speller, Andreas Mayr, Julia Schröder, Axel M. Hillmer, Dominik Heider, Florian Lordick, Ángeles Pérez-Aísa, Rafael Campo, Jesús Espinel, Fernando Geijo, Concha Thomson, Luis Bujanda, Federico Sopeña, Ángel Lanas, María Pellisé, Claudia Pauligk, Thorsten Oliver Goetze, Carolin Zelck, Julian Reingruber, Emadeldin Hassanin, Peter Elbe, Sandra Alsabeah, Mats Lindblad, Magnus Nilsson, Nicole Kreuser, René Thieme, Francesca Tavano, Roberta Pastorino, Dario Arzani, Roberto Persiani, Jin-On Jung, Henrik Nienhüser, Katja Ott, Ralf R. Schumann, Oliver Kumpf, Susen Burock, Volker Arndt, Anna Jakubowska, Małgorzta Ławniczak, Victor Moreno, Vicente Martín, Manolis Kogevinas, Marina Pollán, Justyna Dąbrowska, Antonio Salas, Olivier Cussenot, Anne Boland-Auge, Delphine Daian, Jean-Francois Deleuze, Erika Salvi, Maris Teder-Laving, Gianluca Tomasello, Margherita Ratti, Chiara Senti, Valli De Re, Agostino Steffan, Arnulf H. Hölscher, Katharina Messerle, Christiane Josephine Bruns, Armands Sīviņš, Inga Bogdanova, Jurgita Skieceviciene, Justina Arstikyte, Markus Moehler, Hauke Lang, Peter P. Grimminger, Martin Kruschewski, Nikolaos Vassos, Claus Schildberg, Philipp Lingohr, Karsten Ridwelski, Hans Lippert, Nadine Fricker, Peter Krawitz, Per Hoffmann, Markus M. Nöthen, Lothar Veits, Jakob R. Izbicki, Adrianna Mostowska, Federico Martinón-Torres, Daniele Cusi, Rolf Adolfsson, Geraldine Cancel-Tassin, Aksana Höblinger, Ernst Rodermann, Monika Ludwig, Gisela Keller, Andres Metspalu, Hermann Brenner, Joerg Heller, Markus Neef, Michael Schepke, Franz Ludwig Dumoulin, Lutz Hamann, Renato Cannizzaro, Michele Ghidini, Dominik Plaßmann, Michael Geppert, Peter Malfertheiner, Olivier Gehlen, Tomasz Skoczylas, Marek Majewski, Jan Lubiński, Orazio Palmieri, Stefania Boccia, Anna Latiano, Nuria Aragones, Thomas Schmidt, Mário Dinis-Ribeiro, Rui Medeiros, Salah-Eddin Al-Batran, Mārcis Leja, Juozas Kupcinskas, María A. García-González, Marino Venerito, and Johannes Schumacher

Subjects
Gastric cancer, Oesophageal adenocarcinoma, Genome-wide association study (GWAS), Transcriptome-wide association study (TWAS), Medicine, Medicine (General), R5-920
Abstract

Summary: Background: Gastric cancer (GC) is clinically heterogenous according to location (cardia/non-cardia) and histopathology (diffuse/intestinal). We aimed to characterize the genetic risk architecture of GC according to its subtypes. Another aim was to examine whether cardia GC and oesophageal adenocarcinoma (OAC) and its precursor lesion Barrett’s oesophagus (BO), which are all located at the gastro-oesophageal junction (GOJ), share polygenic risk architecture. Methods: We did a meta-analysis of ten European genome-wide association studies (GWAS) of GC and its subtypes. All patients had a histopathologically confirmed diagnosis of gastric adenocarcinoma. For the identification of risk genes among GWAS loci we did a transcriptome-wide association study (TWAS) and expression quantitative trait locus (eQTL) study from gastric corpus and antrum mucosa. To test whether cardia GC and OAC/BO share genetic aetiology we also used a European GWAS sample with OAC/BO. Findings: Our GWAS consisting of 5816 patients and 10,999 controls highlights the genetic heterogeneity of GC according to its subtypes. We newly identified two and replicated five GC risk loci, all of them with subtype-specific association. The gastric transcriptome data consisting of 361 corpus and 342 antrum mucosa samples revealed that an upregulated expression of MUC1, ANKRD50, PTGER4, and PSCA are plausible GC-pathomechanisms at four GWAS loci. At another risk locus, we found that the blood-group 0 exerts protective effects for non-cardia and diffuse GC, while blood-group A increases risk for both GC subtypes. Furthermore, our GWAS on cardia GC and OAC/BO (10,279 patients, 16,527 controls) showed that both cancer entities share genetic aetiology at the polygenic level and identified two new risk loci on the single-marker level. Interpretation: Our findings show that the pathophysiology of GC is genetically heterogenous according to location and histopathology. Moreover, our findings point to common molecular mechanisms underlying cardia GC and OAC/BO. Funding: German Research Foundation (DFG).

Published
2023
Full Text
View/download PDF

4. Author Correction: Comparison of the management of Helicobacter pylori infection between the older and younger European populations

Author

Paulius Jonaitis, Olga P. Nyssen, Ilaria Maria Saracino, Giulia Fiorini, Dino Vaira, Ángeles Pérez-Aísa, Bojan Tepes, Manuel Castro-Fernandez, Manuel Pabón-Carrasco, Alma Keco-Huerga, Irina Voynovan, Alfredo J. Lucendo, Ángel Lanas, Samuel J. Martínez-Domínguez, Enrique Alfaro Almajano, Luis Rodrigo, Ludmila Vologzanina, Natasa Brglez Jurecic, Maja Denkovski, Luis Bujanda, Umud Mahmudov, Mārcis Leja, Frode Lerang, Gülüstan Babayeva, Dmitry S. Bordin, Antonio Gasbarrini, Juozas Kupcinskas, Oleksiy Gridnyev, Theodore Rokkas, Ricardo Marcos-Pinto, Perminder S. Phull, Sinead M. Smith, Ante Tonkić, Doron Boltin, György Miklós Buzás, Štěpán Šembera, Halis Şimşek, Tamara Matysiak-Budnik, Vladimir Milivojevic, Wojciech Marlicz, Marino Venerito, Lyudmila Boyanova, Michael Doulberis, Lisette G. Capelle, Anna Cano-Català, Leticia Moreira, Francis Mégraud, Colm O’Morain, Javier P. Gisbert, Laimas Jonaitis, and Hp-EuReg investigators

Subjects
Medicine, Science
Published
2023
Full Text
View/download PDF

5. Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg)

Author

Olga P. Nyssen, Pietro Pratesi, Miguel A. Spínola, Laimas Jonaitis, Ángeles Pérez-Aísa, Dino Vaira, Ilaria Maria Saracino, Matteo Pavoni, Giulia Fiorini, Bojan Tepes, Dmitry S. Bordin, Irina Voynovan, Ángel Lanas, Samuel J. Martínez-Domínguez, Enrique Alfaro, Luis Bujanda, Manuel Pabón-Carrasco, Luis Hernández, Antonio Gasbarrini, Juozas Kupcinskas, Frode Lerang, Sinead M. Smith, Oleksiy Gridnyev, Mārcis Leja, Theodore Rokkas, Ricardo Marcos-Pinto, Antonio Meštrović, Wojciech Marlicz, Vladimir Milivojevic, Halis Simsek, Lumir Kunovsky, Veronika Papp, Perminder S. Phull, Marino Venerito, Lyudmila Boyanova, Doron Boltin, Yaron Niv, Tamara Matysiak-Budnik, Michael Doulberis, Daniela Dobru, Vincent Lamy, Lisette G. Capelle, Emilija Nikolovska Trpchevska, Leticia Moreira, Anna Cano-Català, Pablo Parra, Francis Mégraud, Colm O’Morain, Guillermo J. Ortega, Javier P. Gisbert, and on behalf of the Hp-EuReg Investigators

Subjects
Helicobacter pylori, clustering, phenotyping, machine learning, treatment, eradication, Therapeutics. Pharmacology, RM1-950
Abstract

The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection: All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the “most important” variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013–2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin–clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth–quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin–amoxicillin–metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year.

Published
2023
Full Text
View/download PDF

6. Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management

Author

Investigators, Natalia García-Morales, Ángeles Pérez-Aísa, Giulia Fiorini, Bojan Tepes, Manuel Castro-Fernández, Alfredo Lucendo, Irina Voynovan, Luis Bujanda, Ana Garre, Luis Rodrigo, Samuel Jesús Martínez Domínguez, Maja Denkovski, Jose M. Huguet Malavés, Laimas Jonaitis, Renate Bumane, Oleg Zaytsev, Pilar Mata Romero, Jesús Barrio, Luis Fernández-Salazar, Aiman Silkanovna Sarsenbaeva, Inmaculada Ortiz Polo, Sergey Alekseenko, Ilaria Maria Saracino, Dino Vaira, Alma Keco-Huerga, Dmitry Bordin, Antonio Gasbarrini, Frode Lerang, Theodore Rokkas, Juozas Kupčinskas, Marcis Leja, Gulustan Babayeva, Ricardo Marcos Pinto, Ante Tonkić, Sinead Smith, Perminder Phull, Gyorgy M. Buzas, Halis Simsek, Doron Boltin, Oleksiy Gridnyev, Marino Venerito, Vladimir Milivojevic, Núria Torà, Anna Cano-Català, Leticia Moreira, Olga P. Nyssen, Francis Mégraud, Colm O’Morain, Javier P. Gisbert, Ignasi Puig, and on behalf of Hp-EuReg Investigators on behalf of Hp-EuReg

Subjects
diagnostic tests, gastrointestinal endoscopy, Helicobacter pylori, histology, urea breath test
Abstract

Background and aims: Several methods are available to diagnose Helicobacter pylori infection. Our objective was to evaluate the tests used for both the initial diagnosis and the confirmation of eradication after treatment in Europe. Methods: The European Registry on the management of Helicobacter pylori infection is an international, multicentre, prospective, non-interventional registry aiming to evaluate the management of Helicobacter pylori-infected patients in Europe. Countries with at least 100 cases registered from June 2013 to April 2021, and with a validated diagnostic method were analysed. Data were quality reviewed. Results: A total of 34,920 adult patients from 20 countries were included (mean age 51 years; 61% women). To establish the initial diagnosis, invasive tests were performed in 19,801 (71%) patients, non-invasive in 11,369 (41%), and both in 3437 (12%). The most frequent were histology (n = 11,885; 43%), a rapid urease test (n = 10,636; 38%) and an urea breath test (n = 7577; 27%). According to the age, invasive tests were indicated in 11,179 (77%) ≥50 years, and in 8603 (65%)

Published
2023
Full Text
View/download PDF

7. Dissecting the genetic heterogeneity of gastric cancer

Author

Timo Hess, Carlo Maj, Jan Gehlen, Oleg Borisov, Stephan L. Haas, Ines Gockel, Michael Vieth, Guillaume Piessen, Hakan Alakus, Yogesh Vashist, Carina Pereira, Michael Knapp, Vitalia Schüller, Alexander Quaas, Heike I. Grabsch, Jessica Trautmann, Ewa Malecka-Wojciesko, Anna Mokrowiecka, Jan Speller, Andreas Mayr, Julia Schröder, Axel M. Hillmer, Dominik Heider, Florian Lordick, Ángeles Pérez-Aísa, Rafael Campo, Jesús Espinel, Fernando Geijo, Concha Thomson, Luis Bujanda, Federico Sopeña, Ángel Lanas, María Pellisé, Claudia Pauligk, Thorsten Oliver Goetze, Carolin Zelck, Julian Reingruber, Emadeldin Hassanin, Peter Elbe, Sandra Alsabeah, Mats Lindblad, Magnus Nilsson, Nicole Kreuser, René Thieme, Francesca Tavano, Roberta Pastorino, Dario Arzani, Roberto Persiani, Jin-On Jung, Henrik Nienhüser, Katja Ott, Ralf R. Schumann, Oliver Kumpf, Susen Burock, Volker Arndt, Anna Jakubowska, Małgorzta Ławniczak, Victor Moreno, Vicente Martín, Manolis Kogevinas, Marina Pollán, Justyna Dąbrowska, Antonio Salas, Olivier Cussenot, Anne Boland-Auge, Delphine Daian, Jean-Francois Deleuze, Erika Salvi, Maris Teder-Laving, Gianluca Tomasello, Margherita Ratti, Chiara Senti, Valli De Re, Agostino Steffan, Arnulf H. Hölscher, Katharina Messerle, Christiane Josephine Bruns, Armands Sīviņš, Inga Bogdanova, Jurgita Skieceviciene, Justina Arstikyte, Markus Moehler, Hauke Lang, Peter P. Grimminger, Martin Kruschewski, Nikolaos Vassos, Claus Schildberg, Philipp Lingohr, Karsten Ridwelski, Hans Lippert, Nadine Fricker, Peter Krawitz, Per Hoffmann, Markus M. Nöthen, Lothar Veits, Jakob R. Izbicki, Adrianna Mostowska, Federico Martinón-Torres, Daniele Cusi, Rolf Adolfsson, Geraldine Cancel-Tassin, Aksana Höblinger, Ernst Rodermann, Monika Ludwig, Gisela Keller, Andres Metspalu, Hermann Brenner, Joerg Heller, Markus Neef, Michael Schepke, Franz Ludwig Dumoulin, Lutz Hamann, Renato Cannizzaro, Michele Ghidini, Dominik Plaßmann, Michael Geppert, Peter Malfertheiner, Olivier Gehlen, Tomasz Skoczylas, Marek Majewski, Jan Lubiński, Orazio Palmieri, Stefania Boccia, Anna Latiano, Nuria Aragones, Thomas Schmidt, Mário Dinis-Ribeiro, Rui Medeiros, Salah-Eddin Al-Batran, Mārcis Leja, Juozas Kupcinskas, María A. García-González, Marino Venerito, and Johannes Schumacher

Subjects
Genome-wide association study (GWAS), Oesophageal adenocarcinoma, General Medicine, Gastric cancer, Medical Genetics, Settore MED/42 - IGIENE GENERALE E APPLICATA, General Biochemistry, Genetics and Molecular Biology, Medicinsk genetik, Transcriptome-wide association study (TWAS)
Abstract

Background: Gastric cancer (GC) is clinically heterogenous according to location (cardia/non-cardia) and histopathology (diffuse/intestinal). We aimed to characterize the genetic risk architecture of GC according to its subtypes. Another aim was to examine whether cardia GC and oesophageal adenocarcinoma (OAC) and its precursor lesion Barrett's oesophagus (BO), which are all located at the gastro-oesophageal junction (GOJ), share polygenic risk architecture. Methods: We did a meta-analysis of ten European genome-wide association studies (GWAS) of GC and its subtypes. All patients had a histopathologically confirmed diagnosis of gastric adenocarcinoma. For the identification of risk genes among GWAS loci we did a transcriptome-wide association study (TWAS) and expression quantitative trait locus (eQTL) study from gastric corpus and antrum mucosa. To test whether cardia GC and OAC/BO share genetic aetiology we also used a European GWAS sample with OAC/BO. Findings: Our GWAS consisting of 5816 patients and 10,999 controls highlights the genetic heterogeneity of GC according to its subtypes. We newly identified two and replicated five GC risk loci, all of them with subtype-specific association. The gastric transcriptome data consisting of 361 corpus and 342 antrum mucosa samples revealed that an upregulated expression of MUC1, ANKRD50, PTGER4, and PSCA are plausible GC-pathomechanisms at four GWAS loci. At another risk locus, we found that the blood-group 0 exerts protective effects for non-cardia and diffuse GC, while blood-group A increases risk for both GC subtypes. Furthermore, our GWAS on cardia GC and OAC/BO (10,279 patients, 16,527 controls) showed that both cancer entities share genetic aetiology at the polygenic level and identified two new risk loci on the single-marker level. Interpretation: Our findings show that the pathophysiology of GC is genetically heterogenous according to location and histopathology. Moreover, our findings point to common molecular mechanisms underlying cardia GC and OAC/BO. Funding: German Research Foundation (DFG).

Published
2023

8. Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: A Spanish Multicentre Study

Author

Elena Resina, María G. Donday, Samuel J. Martínez-Domínguez, Emilio José Laserna-Mendieta, Ángel Lanas, Alfredo J. Lucendo, Marta Sánchez-Luengo, Noelia Alcaide, Luis Fernández-Salazar, Luisa De La Peña-Negro, Luis Bujanda, Marta Gómez-Ruiz de Arbulo, Javier Alcedo, Ángeles Pérez-Aísa, Raúl Rodríguez, Sandra Hermida, Yanire Brenes, Olga P. Nyssen, and Javier P. Gisbert

Subjects
urea breath test, Helicobacter pylori, Diagnòstic, Diagnosis, stool antigen test, General Medicine, diagnosis
Abstract

The stool antigen test (SAT) represents an attractive alternative for detection of Helicobacter pylori. The aim of this study was to assess the accuracy of a new SAT, the automated LIAISON® Meridian H. pylori SA based on monoclonal antibodies, compared to the defined gold standard 13C-urea breath test (UBT). This prospective multicentre study (nine Spanish centres) enrolled patients ≥18 years of age with clinical indication to perform UBT for the initial diagnosis and for confirmation of bacterial eradication. Two UBT methods were used: mass spectrometry (MS) including citric acid (CA) or infrared spectrophotometry (IRS) without CA. Overall, 307 patients (145 naïve, 162 with confirmation of eradication) were analysed. Using recommended cut-off values (negative SAT < 0.90, positive ≥ 1.10) the sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 67%, 97%, 86%, 92% and 91%, respectively, obtaining an area under the receiver operating characteristic (ROC) curve (AUC) of 0.85. Twenty-eight patients, including seven false positives and 21 false negatives, presented a discordant result between SAT and UBT. Among the 21 false negatives, four of six tested with MS and 11 of 15 tested with IRS presented a borderline UBT delta value. In 25 discordant samples, PCR targeting H. pylori DNA was performed to re-assess positivity and SAT accuracy was re-analysed: sensitivity, specificity, positive predictive value, negative predictive value, accuracy and AUC were 94%, 97%, 86%, 99%, 97% and 0.96, respectively. The new LIAISON® Meridian H. pylori SA SAT showed a good accuracy for diagnosis of H. pylori infection.

Published
2022

9. Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of

Author

Elena, Resina, María G, Donday, Samuel J, Martínez-Domínguez, Emilio José, Laserna-Mendieta, Ángel, Lanas, Alfredo J, Lucendo, Marta, Sánchez-Luengo, Noelia, Alcaide, Luis, Fernández-Salazar, Luisa, De La Peña-Negro, Luis, Bujanda, Marta Gómez-Ruiz de, Arbulo, Javier, Alcedo, Ángeles, Pérez-Aísa, Raúl, Rodríguez, Sandra, Hermida, Yanire, Brenes, Olga P, Nyssen, and Javier P, Gisbert

Abstract

The stool antigen test (SAT) represents an attractive alternative for detection of

Published
2022

10. LA ADMINISTRACIÓN DE LA TERAPIA CUÁDRUPLE CON BISMUTO EN CÁPSULA ÚNICA TRES VECES AL DÍA AUMENTA LA EFICACIA EN COMPARACIÓN CON LA PAUTA CONVENCIONAL DE CUATRO DOSIS DIARIAS: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Ángeles Pérez-Aísa, Olga P. Nyssen, Alma Keco-Huerga, Luis Rodrigo, Alfredo J Lucendo, Blas José Gómez Rodríguez, Juan Ortuño, Mónica Perona, José M. Huguet, Óscar Núñez, Luis Fernández-Salazar, Jesús Barrio, Ángel Lanas, Eduardo Iyo, Pilar Mata Romero, Miguel Fernández- Bermejo, Barbara Gomez, Ana Garre, Judith Gomez-Camarero, Luis Javier Lamuela, Ana Campillo, Luisa C de la Peña-Negro, Manuel Dominguez-Cajal, Luis Bujanda, Diego Burgos-Santamaria, Fernando Bermejo, Víctor González-Carrera, Ramón Pajares, Pedro Almela Notari, Javier Tejedor-Tejada, Montserrat Planella, Itxaso Jiménez, Yolanda Arguedas Lázaro, Antonio Cuadrado-Lavín, Isabel Pérez-Martínez, Edurne Amorena, Jesús M González- Santiago, Teresa Angueira, Virginia Flores, Samuel Jesús Martínez-Domínguez, Manuel Pabón-Carrasco, Benito Velayos, Alicia Algaba, Consuelo Ramírez, Enrique Alfaro Almajano, Manuel Castro-Fernández, Noelia Alcaide, Patricia Sanz Segura, Anna Cano-Català, Natalia García- Morales, Leticia Moreira, Francis Mégraud, Colm O’Morain, Xavier Calvet, and Javier P. Gisbert

Subjects
Hepatology, Gastroenterology
Published
2023

11. 130 - COMPARACIÓN DE LA EFECTIVIDAD DE LOS TRATAMIENTOS ERRADICADORES MÁS FRECUENTES ENTRE LAS POBLACIONES MÁS MAYORES Y MÁS JÓVENES DE EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Paulius Jonaitis, Olga P. Nyssen, Ilaria Maria Saracino, Giulia Fiorini, Dino Vaira, Ángeles Pérez-Aísa, Bojan Tepes, M. Castro-Fernández, Manuel Pabón-Carrasco, Alma Keco-Huerga, Irina Voynovan, Alfredo J Lucendo, Ángel Lanas, Samuel J Martínez-Domínguez, Enrique Alfaro Almajano, Luis Rodrigo, Ludmila Vologzanina, Natasa Brglez Jurecic, Maja Denkovski, Luis Bujanda, Umud Mahmudov, Mrcis Leja, Frode Lerang, Gülüstan Babayeva, Dmitry S. Bordin, Antonio Gasbarrini, Juozas Kupcinskas, Oleksiy Gridnyev, Theodore Rokkas, Ricardo Marcos-Pinto, Perminder S. Phull, Sinead M. Smith, Ante Tonki, Doron Boltin, György Miklós Buzás, Lumír Kunovský, Halis imek, Tamara Matysiak-Budnik, Vladimir Milivojevic, Wojciech Marlicz, Marino Venerito, Lyudmila Boyanova, Michael Doulberis, Lisette G. Capelle, Anna Cano-Català, Leticia Moreira, Francis Mégraud, Colm O’Morain, Javier P. Gisbert, and Laimas Jonaitis

Subjects
Hepatology, Gastroenterology
Published
2023

12. 135 - TENDENCIAS DE PRESCRIPCIÓN DE TRATAMIENTOS ERRADICADORES Y DE SU EFECTIVIDAD EN PACIENTES NAÏVE A LO LARGO DE 10 AÑOS (2013-2022) EN EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Olga P. Nyssen, Laimas Jonaitis, Ángeles Pérez-Aísa, Dino Vaira, Giulia Fiorini, Ilaria Maria Saracino, Bojan Tepes, Dmitry Bordin, Alma Keco- Huerga, Manuel Castro-Fernández, Alfredo Lucendo, Liudmila Vologzhanina, Luis Bujanda, Natasa Brglez Jurecic, Maja Denkovski, Angel Lanas, Samuel Martínez-Dominguez, Enrique Alfaro, Marcis Leja, Renate Bumane, Emin Mammadov, Gulustan Babayeva, Umud Mahmudov, María Caldas, Luis Rodrigo, Frode Lerang, Galyna Fadieienko, Rustam Abdulkhakov, Jose María Huguet Malavés, Oleg Zaytsev, Tatiana Ilchishina, Luis Fernández-Salazar, Noelia Alcaide, Benito Velayos, Aiman Silkanovna Sarsenbaeva, Igor Bakulin, Antonietta G. Gravina, Marco Romano, Mónica Perona, Sergey Alekseenko, Jesús Barrio, Miguel Areia, Óscar Nuñez, Pavel Bogomolov, Blas José Gómez Rodríguez, Manuel Dominguez- Cajal, Judith Gomez Camarero, Manuel Jiménez Moreno, Sotirios Georgopoulos, Pedro Almela Notari, Ante Tonkic, Rinaldo Pellicano, Halis Simsek, Lumír Kunovský, Antonio Gasbarrini, Jose Maria Botargues Bote, Gyorgy M Buzas, Miguel Fernández-Bermejo, Perminder Phull, Marino Venerito, Peter Malfertheiner, Rosa Rosania, Alexander Link, Eduardo Iyo, Juozas Kupinskas, Oleg Shvets, Ricardo Marcos Pinto, Theodore Rokkas, Ilkay Simsek, Sinead Smith, Doron Boltin, Dominique Lamarque, Daniela Dobru, Wojciech Marlicz, Vladimir Milivojevic, Lyudmila Boyanova, Vincent Lamy, Michael Doulberis, Peter Bytzer, Lisette Capelle, Oleksiy Gridnyev, Ari Ristimaki, Anna Cano-Català, Ignasi Puig, Francis Mégraud, Colm O’Morain, and Javier P. Gisbert

Subjects
Hepatology, Gastroenterology
Published
2023

13. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on

Author

Olga P, Nyssen, Dino, Vaira, Ilaria Maria, Saracino, Giulia, Fiorini, María, Caldas, Luis, Bujanda, Rinaldo, Pellicano, Alma, Keco-Huerga, Manuel, Pabón-Carrasco, Elida, Oblitas Susanibar, Alfredo, Di Leo, Giuseppe, Losurdo, Ángeles, Pérez-Aísa, Antonio, Gasbarrini, Doron, Boltin, Sinead, Smith, Perminder, Phull, Theodore, Rokkas, Dominique, Lamarque, Anna, Cano-Català, Ignasi, Puig, Francis, Mégraud, Colm, O'Morain, and Javier P, Gisbert

Abstract

First-lineInternational multicentre prospective non-interventional European Registry onOverall, 500 patients included in the Hp-EuReg were treated with rifabutin (mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump-inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance with treatment was 89%. At least one adverse event was registered in 26% of the patients (most frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukopenia and thrombocytopenia with fever requiring hospitalisation.Rifabutin-containing therapy represents an effective and safe strategy after one or even several failures of

Published
2022

15. The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)

Author

María Caldas, Ángeles Pérez-Aisa, Bojan Tepes, Alma Keco-Huerga, Luis Bujanda, Alfredo J. Lucendo, Luis Rodrigo, Dino Vaira, Luis Fernández-Salazar, Jose M. Huguet, Jorge Pérez-Lasala, Natasa Brglez Jurecic, Galina Fadeenko, Jesús Barrio, Miguel Areia, Juan Ortuño, Rinaldo Pellicano, Marcis Leja, Javier Molina-Infante, Pavel Bogomolov, Sergey Alekseenko, Manuel Domínguez-Cajal, Judith Gómez-Camarero, Vassiliki Ntouli, Samuel J. Martínez-Domínguez, Rafael Ruiz-Zorrilla, Oscar Núñez, Aiman Silkanovna Sarsenbaeva, Pedro Almela, Perminder Phull, Marta Espada, Ignasi Puig, Olga P. Nyssen, Francis Mégraud, Colm O’Morain, Javier P. Gisbert, and on behalf of the Hp-EuReg Investigators

Subjects
statins, Helicobacter pylori, treatment, Therapeutics. Pharmacology, RM1-950
Abstract

Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1–1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59–0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4–2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3–5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.

Published
2021
Full Text
View/download PDF

16. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain

Author

María Caldas, Ángeles Pérez-Aisa, Manuel Castro-Fernández, Luis Bujanda, Alfredo J. Lucendo, Luis Rodrigo, Jose M. Huguet, Jorge Pérez-Lasala, Javier Molina-Infante, Jesús Barrio, Luis Fernández-Salazar, Ángel Lanas, Mónica Perona, Manuel Domínguez-Cajal, Juan Ortuño, Blas José Gómez-Rodríguez, Pedro Almela, Josep María Botargués, Óscar Núñez, Inés Modolell, Judith Gómez, Rafael Ruiz-Zorrilla, Cristóbal De la Coba, Alain Huerta, Eduardo Iyo, Liliana Pozzati, Rosario Antón, Mercé Barenys, Teresa Angueira, Miguel Fernández-Bermejo, Ana Campillo, Javier Alcedo, Ramón Pajares-Villaroya, Marianela Mego, Fernando Bermejo, José Luis Dominguez-Jiménez, Llúcia Titó, Nuria Fernández, Manuel Pabón-Carrasco, Ángel Cosme, Pilar Mata-Romero, Noelia Alcaide, Inés Ariño, Tommaso Di Maira, Ana Garre, Ignasi Puig, Olga P. Nyssen, Francis Megraud, Colm O’Morain, and Javier P. Gisbert

Subjects
Helicobacter pylori, treatment, first-line, second-line, Spain, Therapeutics. Pharmacology, RM1-950
Abstract

The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. “Optimized” H. pylori therapies achieve over 90% success in Spain.

Published
2020
Full Text
View/download PDF

17. Management of antiplatelet and anticoagulant therapy for endoscopic procedures: introduction to novel oral anticoagulants

Author

Martha L. González-Bárcenas and Ángeles Pérez-Aisa

Subjects
antiagregantes, anticoagulantes orales, endoscopia, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

The development of novel antithrombotic therapy in the past few years and its prescription in patients with cardiovascular and circulatory disease has widened the spectrum of drugs that need to be considered when performing an endoscopic procedure. The balance between the thrombotic risk patients carry due to their medical history and the bleeding risk involved in endoscopic procedures should be thoroughly analyzed by Gastroenterologists. New oral anticoagulants (NOACs) impose an additional task. These agents, that specifically target factor IIa or Xa, do not dispose of an anticoagulation monitoring method nor have an antidote to revert their effect, just as with antiplatelet agents. Understanding the fundamental aspects of these drugs provides the necessary knowledge to determine the ideal period the antithrombotic therapy should be interrupted in order to perform the endoscopic procedure, offering maximum safety for patients and optimal results.

Catalog

Books, media, physical & digital resources
See catalog results